Dino's Bar & Grill Message Board

STOCKTALK

We've detected that you're using an ad content blocking browser plug-in or feature. Ads provide a critical source of revenue to the continued operation of Silicon Investor. We ask that you disable ad blocking while on Silicon Investor in the best interests of our community. If you are not using an ad blocker but are still receiving this message, make sure your browser's tracking protection is set to the 'standard' level.

Strategies & Market Trends : Dino's Bar & Grill

Public Reply Prvt Reply Mark as Last Read File

Previous 10 Next 10 Previous Next

To: Goose94 who wrote (74398)	5/19/2020 6:56:06 AM
From: Goose94	Read Replies (2) of 202707

Medicenna Therapeutics (MDNA-T) Mackie Research Spec Buy Target $5 Q4 Results: Financials are less important at this time as MDNA is still a clinical-stage biotech company. Q4 Results: Revenues were $0.0M compared to $0.0M last year vs. our estimate of $0.0M. Net (loss) was ($2.7M) or ($0.07)/share, larger than our estimates of ($1.5M) or ($0.03)/share due to higher-than-expected R&D expenses. Last year’s net (loss) was ($1.0M) or ($0.04)/share. As of Q4 end (Mar.), MDNA had $37.7M in cash and zero debt on its balance sheet. Subsequent to Q4, an additional $5.2M was raised through the overallotment associated with the March financing. The company should have a cash runway into late 2022. We have increased our R&D expense estimates for FY21 – 22.

Report TOU Violation

Share This Post

Public Reply Prvt Reply Mark as Last Read File

Previous 10 Next 10 Previous Next